Talphera Secures $29 Million Through Strategic Private Placement Financing with CorMedix and Institutional Investors Talphera Inc. announces a major financing deal potentially totaling $29 million, with CorMedix as a key investor, aimed at advancing its innovative medical therapies.

Talphera Secures $29 Million Through Strategic Private Placement Financing with CorMedix and Institutional Investors #USA #San_Mateo #Talphera #NEPHRO_CRRT #CorMedix

Talphera Makes Strategic Moves with FDA and Financing for NEPHRO CRRT Study Talphera, Inc. has reached an agreement with the FDA to significantly reduce its NEPHRO CRRT study size and announced a private financing commitment of up to $14.8 million to enhance clinical trials.

Talphera Makes Strategic Moves with FDA and Financing for NEPHRO CRRT Study #United_States #NEPHRO_CRRT #San_Mateo,_California #Talphera_Inc #FDA_Agreement

Talphera's New FDA Agreement Promises Faster Enrollment for Critical Study Talphera, Inc. has secured a crucial FDA agreement for modifications to its NEPHRO CRRT study, aiming to expedite patient enrollment and enhance treatment approaches.

Talphera's New FDA Agreement Promises Faster Enrollment for Critical Study #United_States #San_Mateo #Talphera #Niyad #NEPHRO_CRRT